B-type natriuretic peptide reference interval of newborns from healthy and pre-eclamptic women: a prospective, multicentre, cross-sectional study

David Rodriguez, Gerardo Garcia-Rivas, Estibalitz Laresgoiti-Servitje, Jesus Yañez, Guillermo Torre-Amione, Carlos Jerjes-Sanchez, David Rodriguez, Gerardo Garcia-Rivas, Estibalitz Laresgoiti-Servitje, Jesus Yañez, Guillermo Torre-Amione, Carlos Jerjes-Sanchez

Abstract

Objective: To define and compare the reference interval of B-type natriuretic peptide (BNP) in healthy newborns (HN) from healthy mothers and with severe pre-eclampsia.

Design: Prospective, multicentre, cross-sectional study.

Setting: Four obstetric wards of second-level academic hospitals.

Participants: 167 HN, from 146 healthy and 21 severe pre-eclamptic women. We included newborns from healthy mothers with full-term pregnancies (38 to 42 gestational weeks), who received adequate prenatal care and who had Apgar scores ≥7 at 0 and 5 min. Newborns with chromosomopathies identified during prenatal consultations, those with respiratory distress and those with cardiac or pulmonary disease detected in the first paediatric evaluation were excluded from this study. In the group of pre-eclamptic women, we considered the same inclusion criteria, but the patients also had to meet the diagnostic criteria for pre-eclampsia with severity features, according to the American College of Obstetricians and Gynaecologists guidelines. The same exclusion criteria used for the healthy group were applied to the pre-eclampsia-associated newborn.

Interventions: A single blood sample from the umbilical cord artery after delivery (vaginal or caesarean section).

Primary outcome: Reference level of BNP in HN.

Results: In the HN group, the median BNP was 12.15 pg/mL (IQR 7.7-16.8 pg/mL) and in the pre-eclamptic group 20.8 pg/mL (IQR 5.8-46.5 pg/mL). The reference interval for BNP in HN was 5pg/mL (95% CI 5 to 5) to 34 pg/mL (95% CI 28.4 to 38.8). We identified higher expression of BNP in newborns from pre-eclamptic women overall (p=0.037, r=0.16) and in newborns exposed to stress conditions, such as complications during labour and delivery (p=0.004, r=0.33).

Conclusions: In HN, BNP concentrations at birth were lower than reported in other similar populations. In neonates with stress conditions, the higher expression of this biomarker establishes another possible link between stress and the cardiovascular response.

Trial registration number: NCT02574806; Pre-results.

Keywords: biomarkers; bnp; newborn; preeclampsia; reference interval.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Flow diagram of study and B-type natriuretic peptide (BNP) values.
Figure 2
Figure 2
The distribution of the B-type natriuretic peptide (BNP) values in healthy newborn group. The right-skewed distribution was related to the limit of quantification of the equipment (5 pg/mL). Thus, a logarithmic transformation was performed. However, the distribution remains right-side skewed. Consequently, the reference interval was estimated using the rank-based method for non-parametric distribution.
Figure 3
Figure 3
Box plot of reference interval of B-type natriuretic peptide (BNP) values in the healthy newborn (HN) and pre-eclampsia-associated newborn (PAN) group (whiskers represent 2.5th and 97.5th percentiles).

References

    1. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol 2007;50:2357–68. 10.1016/j.jacc.2007.09.021
    1. Vijlbrief D. Cardiac biomarkers in Neonatology: Utrecht University, 2015.
    1. El-Khuffash A, Molloy EJ. Are B-type natriuretic peptide (BNP) and N-terminal-pro-BNP useful in neonates? Arch Dis Child Fetal Neonatal Ed 2007;92:F320–F324. 10.1136/adc.2006.106039
    1. Yañez J, Rodriguez D, Treviño C, et al. . Stress transient hypertrophic cardiomyopathy and B-type natriuretic peptide role. Pediatr Cardiol 2013;34:702–6. 10.1007/s00246-012-0317-5
    1. Koch A, Singer H. Normal values of B type natriuretic peptide in infants, children, and adolescents. Heart 2003;89:875–8. 10.1136/heart.89.8.875
    1. Ten Kate CA, Tibboel D, Kraemer US. B-type natriuretic peptide as a parameter for pulmonary hypertension in children. A systematic review. Eur J Pediatr 2015;174:1267–75. 10.1007/s00431-015-2619-0
    1. Law YM, Hoyer AW, Reller MD, et al. . Accuracy of plasma B-type natriuretic peptide to diagnose significant cardiovascular disease in children: the Better Not Pout Children! Study. J Am Coll Cardiol 2009;54:1467–75. 10.1016/j.jacc.2009.06.020
    1. Smith J, Goetze JP, Andersen CB, et al. . Practical application of natriuretic peptides in paediatric cardiology. Cardiol Young 2010;20:353–63. 10.1017/S1047951110000211
    1. Koch A, Zink S, Singer H. B-type natriuretic peptide in paediatric patients with congenital heart disease. Eur Heart J 2006;27:861–6. 10.1093/eurheartj/ehi773
    1. Nir A, Lindinger A, Rauh M, et al. . NT-pro-B-type natriuretic peptide in infants and children: reference values based on combined data from four studies. Pediatr Cardiol 2009;30:3–8. 10.1007/s00246-008-9258-4
    1. Backes CH, Markham K, Moorehead P, et al. . Maternal Preeclampsia and Neonatal Outcomes. J Pregnancy 2011;2011:1–7. 10.1155/2011/214365
    1. Resnik JL, Hong C, Resnik R, et al. . Evaluation of B-type natriuretic peptide (BNP) levels in normal and preeclamptic women. Am J Obstet Gynecol 2005;193:450–4. 10.1016/j.ajog.2004.12.006
    1. Hakim J, Senterman MK, Hakim AM. Preeclampsia is a biomarker for vascular disease in both mother and child: the need for a medical alert system. Int J Pediatr 2013;2013:1–8. 10.1155/2013/953150
    1. Inverness Medical, 2009. Triage BNP product insert .
    1. Chaiworapongsa T, Chaemsaithong P, Yeo L, et al. . Pre-eclampsia part 1: current understanding of its pathophysiology. Nat Rev Nephrol 2014;10:466–80. 10.1038/nrneph.2014.102
    1. Determining Laboratory Reference Intervals: CLSI Guideline Makes the Task Manageable. Lab Med 2009;40:75–6. 10.1309/LMEHV3HP39QOFJPA
    1. CLSI Clinical and Laboratory Standards Institute. Defining, establishing, and verifying reference intervals in the clinical laboratory; Approved Guideline-Third Edition. CLSI document EP28-A3c. Wayne, PA: Clinical and Laboratory Standards Institute, 2008.
    1. Katayev A, Balciza C, Seccombe DW. Establishing reference intervals for clinical laboratory test results: is there a better way? Am J Clin Pathol 2010;133:180–6. 10.1309/AJCPN5BMTSF1CDYP
    1. Bernus A, Wagner BD, Accurso F, et al. . Brain natriuretic peptide levels in managing pediatric patients with pulmonary arterial hypertension. Chest 2009;135:745–51. 10.1378/chest.08-0187
    1. Black PH, Garbutt LD, Stress GLD. Stress, inflammation and cardiovascular disease. J Psychosom Res 2002;52:1–23. 10.1016/S0022-3999(01)00302-6
    1. Jerjes-Sanchez C, Garcia N, Leon-Gonzalez ED de, et al. . Significance of biomarker panel including cardiac Troponin I, D-dimer, and B-Type natriuretic peptide in acute aortic dissection. J Cardiol Ther[ Published Online First: 2013].
    1. Gemelli M, Mamì C, Manganaro R, et al. . Effects of the mode of delivery on ANP and renin-aldosterone system in the fetus and the neonate. Eur J Obstet Gynecol Reprod Biol 1992;43:181–4. 10.1016/0028-2243(92)90171-T
    1. Seong WJ, Yoon DH, Chong GO, et al. . Umbilical cord blood amino-terminal pro-brain natriuretic peptide levels according to the mode of delivery. Arch Gynecol Obstet 2010;281:907–12. 10.1007/s00404-009-1253-3
    1. Fortunato G, Carandente Giarrusso P, Martinelli P, et al. . Cardiac troponin T and amino-terminal pro-natriuretic peptide concentrations in fetuses in the second trimester and in healthy neonates. Clin Chem Lab Med 2006;44:834–6. 10.1515/CCLM.2006.144
    1. Mulay S, Varma DR. Placental barrier to atrial natriuretic peptide in rats. Can J Physiol Pharmacol 1989;67:1–4. 10.1139/y89-001
    1. Bakker J, Gies I, Slavenburg B, et al. . Reference values for N-terminal pro-B-type natriuretic peptide in umbilical cord blood. Clin Chem 2004;50:2465 10.1373/clinchem.2004.040253
    1. Zhu R, Nie Z. A Clinical Study of the N-Terminal pro-Brain Natriuretic Peptide in Myocardial Injury after Neonatal Asphyxia. Pediatr Neonatol 2016;57:133–9. 10.1016/j.pedneo.2015.08.001
    1. Omar HR. Acute cardiogenic pulmonary edema with normal BNP: the value of repeat BNP testing. Am J Emerg Med 2015;33:605.e5–e6. 10.1016/j.ajem.2014.10.006
    1. Mir TS, Laux R, Hellwege HH, et al. . Plasma concentrations of aminoterminal pro atrial natriuretic peptide and aminoterminal pro brain natriuretic peptide in healthy neonates: marked and rapid increase after birth. Pediatrics 2003;112:896–9. 10.1542/peds.112.4.896
    1. Mannarino S, Garofoli F, Mongini E, et al. . BNP concentrations and cardiovascular adaptation in preterm and fullterm newborn infants. Early Hum Dev 2010;86:295–8. 10.1016/j.earlhumdev.2010.04.003
    1. Blohm ME, Arndt F, Sandig J, et al. . Cardiovascular biomarkers in paired maternal and umbilical cord blood samples at term and near term delivery. Early Hum Dev 2016;94:7–12. 10.1016/j.earlhumdev.2016.01.001

Source: PubMed

3
Abonneren